Clinical Scorecard: Identifying Risk Factors for Post-Fecal Microbiota Transplant Antibiotic Use in Patients with Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Analysis

At a Glance

Key Highlights

• Non-CDI antibiotic use within 2 months post-FMT increases risk of CDI recurrence.
• Risk factors for post-FMT non-CDI antibiotic use include immunocompromised status, >3 prior non-CDI antibiotic courses, and prior hospitalization for CDI.
• Common indications for non-CDI antibiotics post-FMT are urinary tract infections, respiratory infections, and procedure prophylaxis.

Guideline-Based Recommendations

Diagnosis

• Identify recurrent CDI patients eligible for FMT excluding severe or fulminant cases.
• Assess patient history for immunocompromised status, prior antibiotic exposure, and hospitalization for CDI.

Management

• Administer standardized FMT via colonoscopic or oral routes to restore healthy intestinal microbiota.
• Consider alternative or additional prevention strategies for patients at high risk of post-FMT antibiotic exposure.

Monitoring & Follow-up

• Follow-up at 1, 2, 6, and 12 months post-FMT to monitor CDI recurrence and antibiotic use.
• Collect data through clinical encounters or electronic medical records to track outcomes.

Risks

• Additional non-CDI antibiotic use within 8 weeks post-FMT may impair microbiota restoration and increase CDI recurrence risk.
• Immunocompromised patients and those with multiple prior antibiotic courses are at higher risk for post-FMT antibiotic exposure.

Patient & Prescribing Data

448 patients treated with FMT for recurrent CDI across 6 US institutions

Approximately 10% receive non-CDI antibiotics within 2 months post-FMT; risk factors identified can guide targeted prevention strategies.

Clinical Best Practices

• Screen patients for immunocompromised status and prior antibiotic exposure before FMT.
• Limit non-CDI antibiotic use post-FMT when possible to preserve microbiota restoration.
• Implement antimicrobial stewardship to reduce unnecessary antibiotic exposure in the post-FMT period.
• Use standardized FMT products and protocols to ensure consistency across treatment centers.
• Monitor patients closely post-FMT for infections requiring antibiotics and balance treatment benefits against CDI recurrence risk.

References

• Study on FMT effectiveness and safety in recurrent CDI
• Society guidelines endorsing FMT for rCDI management
• FDA guidance on FMT consent and administration